ALKERMES PLC (ALKS)       28.19  +0.37 (+1.33%)

28.19  +0.37 (+1.33%)

IE00B56GVS15 - Common Stock - After market: 28.19 0 (0%)

ALKERMES PLC28.19

NASDAQ:ALKS (3/31/2023, 7:01:45 PM)+0.37 (+1.33%)

After market: 28.19 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)02-16 2023-02-16/bmo
Earnings (Next)N/A N/A
Ins Owners1.26%
Inst Owners98.55%
Market Cap4.63B
Shares164.39M
PE82.91
Fwd PE299.43
Dividend YieldN/A
Analysts75.29
IPO07-16 1991-07-16

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALKS Daily chart

Company Profile

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Company Info

ALKERMES PLC

Connaught HSE, 1 Burlington Road

DUBLIN DUBLIN DUBLIN 4

P: 35317728000.0

CEO: Richard F. Pops

Employees: 2280

Website: http://www.alkermes.com/

ALKS News

News Image2 days ago - Market News VideoNotable Thursday Option Activity: SMG, ALKS, MUNews Image4 days ago - Investor's Business DailyAlkermes Stock Sees Rising Relative Strength Rating

The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.

News Image9 days ago - Alkermes plcJournal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI® (olanzapine and...

News Image15 days ago - Market News VideoAlkermes Breaks Below 200-Day Moving Average - Notable for ALKSNews Image17 days ago - Alkermes plcAlkermes to Participate in the Stifel 2023 CNS Days

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on...

News Image17 days ago - InvestorPlaceThe 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

ALKS Twits

Here you can normally see the latest stock twits on ALKS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example